Related Experiment Video
Updated: Feb 6, 2026
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
Targeting Focal Adhesion Kinase Using Inhibitors of Protein-Protein Interactions
Antoine Mousson1,2, Emilie Sick3,4, Philippe Carl5,6
1Faculté de Pharmacie, Université de Strasbourg, 67401 Illkirch, France. antoine.mousson@etu.unistra.fr.
Abstract:
Focal adhesion kinase (FAK) is a cytoplasmic non-receptor protein tyrosine kinase that is overexpressed and activated in many human cancers. FAK transmits signals to a wide range of targets through both kinase-dependant and independent mechanism thereby playing essential roles in cell survival, proliferation, migration and invasion. In the past years, small molecules that inhibit FAK kinase function have been developed and show reduced cancer progression and metastasis in several preclinical models. Clinical trials have been conducted and these molecules display limited adverse effect in patients. FAK contain multiple functional domains and thus exhibit both important scaffolding functions. In this review, we describe the major FAK interactions relevant in cancer signalling and discuss how such knowledge provide rational for the development of Protein-Protein Interactions (PPI) inhibitors.
Insights
Focal adhesion kinase (FAK) is crucial in cancer progression. Inhibiting its kinase function shows promise in preclinical models, with early clinical trials indicating limited adverse effects, paving the way for new therapies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Focal adhesion kinase (FAK) is a non-receptor protein tyrosine kinase.
- FAK is frequently overexpressed and activated in various human cancers.
- It plays critical roles in cancer cell survival, proliferation, migration, and invasion.
Purpose of the Study:
- To review major FAK interactions in cancer signaling.
- To discuss the development of FAK kinase inhibitors.
- To explore rationales for developing Protein-Protein Interactions (PPI) inhibitors targeting FAK.
Main Methods:
- Literature review of FAK signaling pathways.
- Analysis of preclinical data for FAK inhibitors.
- Review of clinical trial outcomes for FAK-targeted therapies.
Main Results:
- FAK signaling involves both kinase-dependent and independent mechanisms.
- Small molecule FAK kinase inhibitors have demonstrated efficacy in reducing cancer progression and metastasis in preclinical models.
- Clinical trials indicate that FAK inhibitors have a manageable adverse effect profile.
Conclusions:
- FAK's multifaceted roles, including scaffolding functions, are vital in cancer.
- Targeting FAK kinase activity is a viable therapeutic strategy.
- Understanding FAK interactions can guide the development of novel Protein-Protein Interactions (PPI) inhibitors for cancer treatment.
More Related Videos
06:06Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles
Published on: March 9, 2019
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Related Concept Videos
02:54Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
02:54Protein Kinases and Phosphatases
02:04Protein-protein Interfaces
01:17Intracellular Signaling Affects Focal Adhesions
Some...
01:25cAMP-dependent Protein Kinase Pathways
00:55Laminins are the Adhesive Proteins of Basal Lamina
In humans, the five forms of alpha chains are LAMA 1, LAMA 2, LAMA 3, LAMA 4, and LAMA 5. The four forms of beta chains are LAMB 1, LAMB 2, LAMB 3, and LAMB 4. The three forms of gamma...